| Here's Why Labcorp (LH) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-15 14:56:18 |
Czytaj oryginał (ang.) |
| 3 Dental Supplies Stocks Likely to Gain From US-China Trade Deal |
Here we discuss three stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, LH and ALGN. |
zacks.com |
2025-05-13 12:20:38 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Labcorp (LH) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-12 14:45:47 |
Czytaj oryginał (ang.) |
| Labcorp to Webcast Its Annual Meeting of Shareholders May 15 |
BURLINGTON, N.C., May 8, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m. |
prnewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| LH vs. MMSI: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Labcorp (LH) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-05-05 16:46:15 |
Czytaj oryginał (ang.) |
| Why Labcorp (LH) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-01 14:40:46 |
Czytaj oryginał (ang.) |
| Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript |
Labcorp Holdings Inc. (NYSE:LH ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Christin O'Donnell - Investor Relations Adam Schechter - Chairman & Chief Executive Officer Julia Wang - Executive Vice President & Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Ann Hynes - Mizuho Securities Erin Wright - Morgan Stanley Elizabeth Anderson - Evercore ISI Lisa Gill - JPMorgan Jack Meehan - Nephron Research Luke Sergott - Barclays Kevin Caliendo - UBS Michael Ryskin - Bank of America Patrick Donnelly - Citi Eric Coldwell - Baird Kieran Ryan - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Q1 2025 Labcorp Holdings Earnings Conference Call. |
seekingalpha.com |
2025-04-29 20:21:03 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-04-29 14:35:45 |
Czytaj oryginał (ang.) |
| Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains |
LH delivers better-than-expected earnings in the first quarter of 2025. |
zacks.com |
2025-04-29 13:56:07 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Beats Q1 Earnings Estimates |
Labcorp (LH) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.68 per share a year ago. |
zacks.com |
2025-04-29 13:01:04 |
Czytaj oryginał (ang.) |
| Labcorp Announces 2025 First Quarter Results |
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date Introduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid in the diagnosis of Alzheimer's disease BURLINGTON, N.C. , April 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance. |
prnewswire.com |
2025-04-29 10:50:00 |
Czytaj oryginał (ang.) |
| Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions |
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments. |
prnewswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Earnings Expected to Grow: Should You Buy? |
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-22 15:07:29 |
Czytaj oryginał (ang.) |
| Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth |
LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses. |
zacks.com |
2025-04-16 15:20:35 |
Czytaj oryginał (ang.) |
| Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics |
Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand. Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily. The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare. Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand. |
globenewswire.com |
2025-04-11 09:32:00 |
Czytaj oryginał (ang.) |
| Labcorp Declares Quarterly Dividend |
BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. |
prnewswire.com |
2025-04-10 10:50:00 |
Czytaj oryginał (ang.) |
| Is it the Right Time to Retain Labcorp Stock in Your Portfolio? |
LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus. |
zacks.com |
2025-04-09 14:55:35 |
Czytaj oryginał (ang.) |
| Here's Why Labcorp (LH) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-03 14:45:41 |
Czytaj oryginał (ang.) |
| LH Stock to Gain From Launch of HPV and STI Self-Collection Options |
Labcorp launches self-collection options for HPV and STI testing in its PSCs. |
zacks.com |
2025-04-02 14:46:08 |
Czytaj oryginał (ang.) |
| Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease |
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. |
prnewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Labcorp (LH) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-26 12:45:51 |
Czytaj oryginał (ang.) |
| Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors |
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors. |
prnewswire.com |
2025-02-24 09:32:00 |
Czytaj oryginał (ang.) |
| Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold' |
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects. |
seekingalpha.com |
2025-02-13 16:12:56 |
Czytaj oryginał (ang.) |
| Why Labcorp (LH) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-12 12:51:08 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Labcorp (LH) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-11 12:46:31 |
Czytaj oryginał (ang.) |
| Here's Why Labcorp (LH) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-11 12:46:09 |
Czytaj oryginał (ang.) |
| Why Labcorp (LH) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-10 12:40:33 |
Czytaj oryginał (ang.) |
| Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript |
Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions]. |
seekingalpha.com |
2025-02-06 17:42:03 |
Czytaj oryginał (ang.) |
| Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook |
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39. |
benzinga.com |
2025-02-06 15:22:52 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-06 12:36:38 |
Czytaj oryginał (ang.) |
| Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles |
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024. |
zacks.com |
2025-02-06 12:21:13 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates |
Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago. |
zacks.com |
2025-02-06 11:01:11 |
Czytaj oryginał (ang.) |
| Labcorp forecasts 2025 revenue above estimates on diagnostic test demand |
Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests. |
reuters.com |
2025-02-06 08:55:56 |
Czytaj oryginał (ang.) |
| Labcorp Announces 2024 Fourth Quarter and Full Year Results |
Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 million Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024 Full-Year 2025 Guidance: Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4% Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8% Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2% BURLINGTON, N.C. , Feb. 6, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance. |
prnewswire.com |
2025-02-06 08:50:00 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Beyond analysts' top -and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-04 12:20:30 |
Czytaj oryginał (ang.) |
| Labcorp Set to Report Q4 Earnings: What's in Store for the Stock? |
In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services. |
zacks.com |
2025-01-31 12:06:25 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Earnings Expected to Grow: Should You Buy? |
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-30 13:07:21 |
Czytaj oryginał (ang.) |
| LH or ALGN: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or Align Technology (ALGN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-29 14:40:28 |
Czytaj oryginał (ang.) |
| Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference |
BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. |
prnewswire.com |
2025-01-10 18:15:00 |
Czytaj oryginał (ang.) |
| Why Labcorp (LH) is Poised to Beat Earnings Estimates Again |
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-09 15:11:32 |
Czytaj oryginał (ang.) |
| LH vs. WST: Which Stock Is the Better Value Option? |
Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-03 14:51:11 |
Czytaj oryginał (ang.) |
| Is Labcorp (LH) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-03 12:45:51 |
Czytaj oryginał (ang.) |
| Should You Retain Labcorp Stock in Your Portfolio Right Now? |
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships. |
zacks.com |
2025-01-03 10:05:42 |
Czytaj oryginał (ang.) |
| Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock |
LH announces strategic agreement with Graves Gilbert Clinic for lab operations. |
zacks.com |
2024-12-26 12:55:20 |
Czytaj oryginał (ang.) |
| Labcorp Launches H5 Bird Flu Test Amid US Outbreak: Stock to Gain? |
LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States. |
zacks.com |
2024-12-19 10:31:10 |
Czytaj oryginał (ang.) |
| LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal |
Labcorp is set to acquire select assets of MAWD Pathology Group. |
zacks.com |
2024-12-17 10:06:21 |
Czytaj oryginał (ang.) |
| Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians |
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu. |
prnewswire.com |
2024-12-17 09:00:00 |
Czytaj oryginał (ang.) |
| Be Patient, Earn Dividends From Labcorp, The Leading Patient Clinical Lab Brand |
For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth indicators through the growth of new locations and acquisitions, but also expected future patient demand for diagnostics. The company's main competitor/peer in this niche is Quest Diagnostics, and Labcorp struggles with a weak profit margin and growth in expenses. |
seekingalpha.com |
2024-11-29 14:16:49 |
Czytaj oryginał (ang.) |
| Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients |
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. |
prnewswire.com |
2024-11-26 09:52:00 |
Czytaj oryginał (ang.) |
| Cinven secures Italian nod to sell minority stake in Synlab to Labcorp |
Private equity firm Cinven secured a conditional approval from Italian authorities over its plan to sell a 15% stake in diagnostic service provider Synlab to laboratory operator Labcorp , a government document sent to parliament showed. |
reuters.com |
2024-11-20 06:23:51 |
Czytaj oryginał (ang.) |
| Labcorp CFO Glenn Eisenberg Announces Plans to Retire |
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. |
prnewswire.com |
2024-11-19 09:00:00 |
Czytaj oryginał (ang.) |
| Is Labcorp Stock a Good Pick for Your Portfolio Right Now? |
Investors are increasingly optimistic about LH due to its partnerships and operational discipline. |
zacks.com |
2024-11-15 10:36:09 |
Czytaj oryginał (ang.) |
| Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain? |
LH launches new enhancements to Global Trial Connect to streamline site workflow. |
zacks.com |
2024-11-13 11:25:28 |
Czytaj oryginał (ang.) |
| Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript |
Labcorp Holdings Inc. (NYSE:LH ) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Ann Hynes – Mizuho Lisa Gill – JPMorgan Michael Cherny – Leerink Partners Patrick Donnelly – Citi Erin Wright – Morgan Stanley David Westenberg – Piper Sandler Jack Meehan – Nephron Research Pito Chickering – Deutsche Bank Andrew Brackmann – William Blair Kevin Caliendo – UBS Elizabeth Anderson – Evercore ISI Eric Coldwell – Baird Stephanie Davis – Barclays John Kim – Bank of America Operator Good day and thank you for standing by. Welcome to the Q3 2024 Labcorp Holdings Earnings Conference Call. |
seekingalpha.com |
2024-10-24 18:00:05 |
Czytaj oryginał (ang.) |
| LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains |
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum. |
zacks.com |
2024-10-24 16:16:10 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics |
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-10-24 15:35:27 |
Czytaj oryginał (ang.) |
| Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact |
Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49. |
benzinga.com |
2024-10-24 15:25:41 |
Czytaj oryginał (ang.) |
| Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates |
Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago. |
zacks.com |
2024-10-24 13:01:12 |
Czytaj oryginał (ang.) |
| Labcorp beats quarterly estimates on diagnostic test demand |
Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests. |
reuters.com |
2024-10-24 11:10:52 |
Czytaj oryginał (ang.) |
| Labcorp Announces 2024 Third Quarter Results |
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance: Revenue range of 6.6% to 7.3%; midpoint unchanged Adjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15 Free Cash Flow of $850 million to $980 million Announced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiatives BURLINGTON, N.C. , Oct. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2024 and updated full-year guidance. |
prnewswire.com |
2024-10-24 10:50:00 |
Czytaj oryginał (ang.) |